title: [Establishment of cisplatin-induced multidrug resistant human epithelial ovarian cancer cell line 3AO/cDDP and its expressions of multidrug resistance proteins].
abstract: OBJECTIVE
  To establish multidrug resistant ovarian cancer cell line 3AO/cDDP by exposing parent cell line intervally and repeatedly to high-level concentration of cisplatin, and to detect expressions of lung resistance protein (LRP), multidrug resistance-associated protein(MRP) and P-glycoprotein (P-gp).
  
  
  METHODS
  Using the corresponding dose calculated from clinical chemotherapy, we established 3AO/cDDP, with 3AO exposed intervally and repeatedly to high-level concentration of cisplatin at 10 micrograms/ml for 24 hours each time; LRP, MRP and P-gp expressions were detected with flow cytometry(FCM).
  
  
  RESULTS
  3AO/cDDP was established after 4.5 months with stable resistance and the drug resistant index was 1.62 which was similar to clinical resistance degree. Low expression levels of MRP and P-gp were found in both 3AO and 3AO/cDDP, and no statistical difference between the two lines (P > 0.05). However, LRP expression level in 3AO/cDDP was significantly higher than that in 3AO with FCM detection (P < 0.01).
  
  
  CONCLUSIONS
  3AO/cDDP, induced by exposing 3AO to high-level concentration of cisplatin intervally and repeatedly, is an ideal model for investigation of cisplatin resistance. Cisplatin resistance in 3AO/cDDP could be related to high LRP expression and be not associated with MRP or P-gp.
authors.affiliation: Department of Obstetrics, Hospital of Obstetrics and Gynecology, Shanghai Medical University, Shanghai 200011, China.
authors.forename: J
authors.initials: J
authors.lastname: Chen
authors.forename: R
authors.initials: R
authors.lastname: Yang
authors.forename: F
authors.initials: F
authors.lastname: Liu
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology*; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000096:biosynthesis*; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009375:Neoplasms, Glandular and Epithelial / Q000378:metabolism / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology*; D014407:Tumor Cells, Cultured; D020394:Vault Ribonucleoprotein Particles / Q000096:biosynthesis*; D000099187:Major Vault Protein
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D002945:Cisplatin; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D009363:Neoplasm Proteins; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein